Enanta Pharmaceuticals Announces the Appointment of Nathalie Adda, M.D. as Chief Medical Officer
June 30 2015 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced the appointment of Nathalie Adda, M.D., as Senior Vice
President and Chief Medical Officer, responsible for clinical and
regulatory affairs.
“Nathalie is a welcome addition to our executive management
team. Her clinical and regulatory expertise will be invaluable to
us as we prepare to advance our internal virology and liver disease
programs,” commented Jay R. Luly, Ph.D., President and CEO.
Dr. Adda is a specialist in infectious disease and has more than
15 years of experience in the pharmaceutical industry in all phases
of global clinical research and development and commercialization.
Most recently, Dr. Adda was Chief Medical Officer, VP Clinical
Development, Medical and Regulatory Affairs at Transgene SA, where
she led the Oncology and Infectious Disease programs since 2012.
From 2006 to 2012, she was Senior Medical Director and the medical
lead for the Incivek® (telaprevir) Clinical Program at Vertex
Pharmaceuticals Inc., where she designed the phase 2 and Phase 3
programs, and led the medical team in its successful marketing
applications and registration in the USA, Canada, and, Asia.
Earlier in her career, she held medical and research positions at
Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where
she worked on programs for infectious diseases such as human
immunotherapy virus, hepatitis B virus and hepatitis C virus.
Dr. Adda is a graduate of the University of Paris, where she
received a Doctorate in Medicine, as well as a Master’s Degree in
Biostatistics, and where she did post-graduate work in infectious
diseases.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta is discovering, and in some cases developing, novel
inhibitors designed for use against the hepatitis C virus (HCV).
These inhibitors include members of the direct acting antiviral
(DAA) inhibitor classes – protease (partnered with AbbVie), NS5A,
and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Enanta’s lead
protease inhibitor, paritaprevir, is part of AbbVie’s recently
approved HCV treatment regimens. In addition, Enanta has a
preclinical program in non-alcoholic steatohepatitis, or NASH,
which is a condition that results in liver inflammation and damage
caused by a buildup of fat in the liver.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150630005254/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024